Cabometyx

About Royalty Pharma

Royalty Pharma is a pioneer and dominant leader in the biopharmaceutical royalty financing sector, having deployed over $25 billion in capital since its 1996 founding. Its mission is to fund the next wave of biopharma innovation by providing non-dilutive capital to partners in exchange for a share of future royalty streams. The company's strategy centers on building a diversified portfolio of royalties across therapeutic areas and development stages, leveraging deep scientific and financial expertise to structure bespoke deals that fuel R&D while generating predictable, long-duration cash flows for investors.

Therapeutic Areas

Other Renal Cell Carcinoma, Hepatocellular Carcinoma Drugs